Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Uterine Cervical Neoplasms 2Neuroendocrine Tumors 2Vaginal Neoplasms 1Lymphoma, Follicular 1Glioblastoma 1Endometrial Serous Adenocarcinoma 1Astrocytoma 1

Interventions

Lenalidomide 12Cyclophosphamide 12Rituximab 11Prednisone 9obinutuzumab 7Vincristine 7Magnetic Resonance Spectroscopy 7Doxorubicin 7Bendamustine Hydrochloride 6Specimen Handling 5Biopsy 5fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Radiotherapy 3R-CHOP protocol 3Cyclosporine 3zanubrutinib 2tazemetostat 2pembrolizumab 2ibrutinib 2Temozolomide 2Prednisolone 2Peripheral Blood Stem Cell Transplantation 2Oxaliplatin 2Mycophenolic Acid 2Melphalan 2Gemcitabine 2Etoposide 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 30 days × Clear all
NCT06860594 2026-06-05

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡